[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Active, not recruiting · Phase 1 · NCT06229366
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
At a glance
- Research payments reported, 2025
- $15,050
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 142
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- [Ac-225]-PSMA-62 (mCRPC) (drug), [Ac-225]-PSMA-62 (OmHSPC) (drug)
- Dates
- Started 2024-04-03; completion 2032-12
- Results posted
- Not yet
ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $15,050 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hoag Memorial Hospital Presbyterian $15,050
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.